Hester Biosciences is currently trading at Rs 764.90, up by 9.05 points or 1.20% from its previous closing of Rs. 755.85 on the BSE.
The scrip opened at Rs 769.80 and has touched a high and low of Rs 772.00 and Rs 742.20 respectively. So far 1979 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 825.00 on 29-Jul-2016 and a 52 week low of Rs. 337.00 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 772.00 and Rs. 725.00 respectively. The current market cap of the company is Rs. 647.54 crore.
The promoters holding in the company stood at 54.07%, while Institutions and Non-Institutions held 1.83% and 44.10% respectively.
Hester Biosciences reported 21.85% rise in its net profit at Rs 5.80 crore for the quarter ended December 31, 2016 as compared to Rs 4.76 crore for the same quarter in the previous year. Total income from operation of the company increased by 17.95% at Rs 28.52 crore for Q3FY17 as compared Rs 24.18 crore for the corresponding quarter previous year.
Hester Biosciences is one of India’s leading animal healthcare companies and second largest poultry vaccine manufacturer. Located near Ahmedabad, Gujarat, Hester has a state-of-the-art manufacturing facility for products ranging from vaccines, health products to diagnostics. Hester’s services include seroprofiling for poultry flocks and mastitis control programs for cattle.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1807.25 |
| Dr. Reddys Lab | 1273.90 |
| Cipla | 1388.80 |
| Zydus Lifesciences | 1104.35 |
| Lupin | 2292.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: